Background {#Sec1}
==========

Hemorrhagic transformation (HT), either asymptomatic (AHT) or symptomatic (SHT), is considered to be a notorious complication of acute ischemic stroke (AIS), associated with limited treatment options and long-term adverse outcomes \[[@CR1]\]. It seems reasonable that efforts should be directed towards preventing HT before it occurs. Fortunately, it is more predictable than other types of intracranial hemorrhage.

In AIS patients, the incidence of HT induced by intravenous recombinant tissue plasminogen activator (IV rtPA) is reported to be 4.5--39.6% for AHT and 5.2--7.3% for SHT. In contrast, the rate of spontaneous AHT and SHT ranges from 13% to 43% and from 0.6% to 20% respectively \[[@CR2], [@CR3]\]. Although the proportion of AIS patients treated with IV rtPA is relatively small (4.7--21.4%) \[[@CR4]\], the majority of authors have focused on searching HT predictors coupled with IV rtPA over the past decade. As a result, a variety of predictive clinical scores have emerged \[[@CR5]--[@CR9]\].

On the other hand, there is a lack of tools for making an accurate HT prediction in AIS patients who are not eligible for IV rtPA. That is especially important in the light of missing evidence-based data concerning the timing of anticoagulant resumption after AIS in patients with atrial fibrillation (AF). Recommendations on the initiation of anticoagulation are currently based on consensus opinion, in what is known as the "1--3--6--12 day rule" \[[@CR10]\]. Therefore, the two-week timeframe following the AIS onset is the most critical for developing HT. In this instance, an accurate prediction of HT could make a difference in decision making to reinstitute anticoagulation. The middle cerebral artery (MCA) is by far the largest cerebral artery and is the vessel most commonly affected by cerebrovascular accident.

Given the background, we aimed to develop a simple and yet reliable instrument called the hemorrhagic transformation index (HTI) to predict any HT within 14 days after AIS onset in the MCA territory regardless of the use of IV rtPA.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Using prospectively collected clinical and radiological databases, we retrospectively identified 783 consecutive patients with AIS in the MCA territory who were admitted to the stroke unit of the Interregional Clinical Diagnostic Center, Kazan, Russia, within 12 h after onset between January 2013 and May 2016. The exclusion criteria were: involvement of other vascular territories; AIS following any surgery or endovascular procedure within 1 month; brain ischemic lesions due to an intracranial tumor, infection, cerebral venous thrombosis, subarachnoid hemorrhage, and arteriovenous malformation/fistula. In total, 1361 AIS patients were admitted over the specified period. The sample was drawn from the local Caucasian population.

The eligible patients received diagnostic tests and treatment in accordance with current national stroke guidelines. The permissible hospital length of stay was at least 14 days, which was determined by the state mandatory medical insurance standard for AIS patients.

Clinical baseline variables, including age, sex, risk factors, pre-admission medication, stroke subtype according to the Trial of ORG 10172 in Acute Stroke Treatment classification, NIHSS score, vital signs, blood tests, electrocardiogram (ECG), echocardiogram, and chest X-ray findings at admission were extracted from the medical charts. The NIHSS score was routinely and systematically assessed by neurologists. The time of AIS onset was documented as described by the patient or witness; if unknown, it was considered to be the last time the patient was seen well. In-hospital antithrombotic medication was logged for 14 consecutive days; the log was withdrawn earlier if HT occurred.

Imaging protocol {#Sec4}
----------------

Brain non-contrast computed tomography (CT) was performed using a multidetector CT scanner (Aquilion 64; Toshiba Medical Systems, Otawara, Japan). All CT scans were obtained with 0.5 mm slice thickness; the technical parameters were as follows: 120 kVp, 300 mA, rotation time 0.75 s, matrix size 512 × 512, helical scan mode, total scan time 9.7 s, reconstruction interval 5 mm. Window levels and widths were optimized for gray/white matter distinction. The Alberta Stroke Program Early CT score (ASPECTS), hyperdense MCA (HMCA) sign, and leukoaraiosis were routinely and systematically recorded at admission by radiologists. The HMCA sign was assessed by measurements of absolute attenuation of the affected and normal vessels. Absolute density of the affected MCA of \>43 Hounsfield units and the MCA ratio of \>1.2 on a non-contrast CT scan were regarded as the positive HMCA sign \[[@CR11]\]. Diffuse hypodense areas involving the periventricular and/or centrum semiovale white matter were considered as leukoaraiosis. A follow-up CT scan was routinely done on hospitalization day 7 and 14 or at any time if required by a treating neurologist. All patients had at least one follow-up CT scan.

Outcome measures {#Sec5}
----------------

The outcome was retrospectively revised based on prospectively collected data. Any HT on a follow-up CT scan within 14 days after AIS onset was taken into account. A hemorrhage was considered symptomatic if it was not seen on a previous CT scan and there had subsequently been either a suspicion of hemorrhage or any decline in neurologic status \[[@CR12]\]. According to the ECASS I trial \[[@CR13]\], HT was further classified into hemorrhagic infarction type 1 (HI-1), or type 2 (HI-2), or parenchymal hematoma type 1 (PH-1), or type 2 (PH-2).

Statistical analysis {#Sec6}
--------------------

Multinomial logistic regression with relative risk ratio (RRR) estimation was used to highlight the AHT and SHT association with poor outcomes (death, malignant edema, and dependency defined as the modified Rankin scale of \>2 at discharge); the baseline category was the HT-negative group.

The intraclass correlation coefficient (ICC) was computed to assess inter-rater agreement for the ASPECTS and NIHSS. In order to calculate the ICC for the NIHSS, the same set of video files with NIHSS examination from six patients with different stroke severity was demonstrated to seven neurologists who regularly admitted patients to our stroke unit. The ICC for the ASPECTS was obtained in the similar manner: the identical pool of brain non-contrast CT scans from 33 patients with different ischemic burden was presented to four radiologists, who regularly evaluated brain CT scans at admission. Each doctor was evaluated separately and independently; the NIHSS and ASPECTS reference manuals were available on request. He or she had a chance to make any corrections during the evaluation process, but was not allowed to do so after his or her assessment had been completed.

A preliminary data analysis showed that 14 variables in 39.21% of observations were missing (Table [1](#Tab1){ref-type="table"}).Table 1Variables with Missing ValuesMissing, *n* (%)Valid, *n*Cholesterol, total107 (13.7)676LVEF80 (10.2)703AST61 (7.8)722Bilirubin, total55 (7)728Fibrinogen41 (5.2)742Albumin37 (4.7)746Protein, total18 (2.3)765Sodium11 (1.4)772Potassium10 (1.3)773Prothrombin time5 (0.6)778ALT4 (0.5)779Urea2 (0.3)781Hematocrit2 (0.3)781Hemoglobin1 (0.1)782*Note*: *ALT* stands for Alanine transaminase, *AST* Aspartate transaminase, and *LVEF* Left ventricular ejection fraction (echocardiography, Simpson method)

The data were not missing completely at random (Little's test: χ^2^(1706), 2336.69; *p* \< 0.001). However, the omissions did occur accidentally because some tests were not available at the time of patient's admission or the results were lost. Moreover, the missing variables correlated with other collected data. Therefore, it was reasonable to assume that the data were missing at random and multiple imputation (MI) was an appropriate technique to manage the absent values (Table [2](#Tab2){ref-type="table"}).Table 2MI SpecificationSoftware packageIBM SPSS Statistics, v.24; Armonk, NYRandom number generatorMersenne twisterImputation methodFully conditional specification (MCMC)Model typeLinear regression, no interaction termsNumber of iterations100PredictorsAll collected data, including missing variablesRestrictionsExtrema of source dataNumber of imputations15Quality of MINo pattern on MCMC convergence charts\
FMI, RIV, RE (Table [4](#Tab4){ref-type="table"})*Note*: *FMI* stands for Fraction of missing information, *MCMC* Markov chain Monte Carlo, *RE* Relative efficiency, and *RIV* Relative increase in variance

After obtaining the imputed data, the observations were divided into derivation (DC) and validation (VC) cohorts by generating Bernoulli variates with probability parameter 0.7.

Descriptive statistics included median with interquartile range (IQR) and percentage for continuous (the distribution was not normal) and categorical data respectively. The NIHSS and ASPECTS were treated as continuous variables because of multiple categories. Lists of univariate and multivariate HT predictors were obtained by fitting a binary logistic regression (BLR) model. Variables with univariate *p*-value ≤0.25 were further included in multivariate analysis, whereas only items with *p*-value \<0.05 were kept in the multivariate BLR equation. Once the list of HT predictors was obtained by fitting a multivariate BLR model, we dropped the MI dataset because the included variables had no missing values in the source data.

In order to proceed with exploratory (EFA) and confirmatory (CFA) factor analysis, the Bartlett's test of sphericity, Kaiser-Meyer-Olkin measure, and Doornik-Hansen test were carried out to check for patterned relationships between the HTI items, data sufficiency, and multivariate normality respectively. EFA by means of principal factor (PF) and principal component factor (PCF) techniques was performed with varimax and promax rotations to assess dimensionality of the HTI items and to extract variables with shared variance; an eigenvalue cut-off was 1.0. CFA with maximum likelihood estimation was applied to select the final model; goodness of fit was assessed with the Satorra-Bentler scaled χ^2^ test to adjust for data non-normality.

HTI internal consistency reliability (ICR) was evaluated with the ordinal α, Guttman λ~2~ and λ~4~ bounds, Raykov's ρ, McDonald's ω, and greatest lower bound \[[@CR14], [@CR15]\]. The values ≥0.7 were considered to be reliable. As the model included ordinal and dichotomous variables, a polychoric correlation matrix was used for EFA and ICR analysis except for McDonald's categorical ω. The latter was computed by using the Green and Yang method \[[@CR16]\].

The DC and VC were compared by using the Mann-Whitney U and Pearson χ^2^ tests for continuous and categorical variables respectively. The equality of kernel density estimate (KDE) for predicted probability (PP) of any HT between the multivariate BLR model and HTI score as well as for HTI scores between the DC and VC was evaluated with the two-sample Kolmogorov-Smirnov test.

Receiver operating characteristic (ROC) analysis was conducted to assess prognostic performance. The optimal cutpoint score to distinguish between HT-positive and negative groups was defined with the Youden index. Based on the VC appraisal, the predictive ability of the HTI was compared with several alternative tools by testing the area under the ROC curve (AUC) of each score against the HTI one. For each comparison, the Šidák-adjusted *p*-value was reported. The AUC equality was evaluated by using the DeLong algorithm \[[@CR17]\].

Whenever possible, bootstrapping was performed with 1000 samples and computing either adjusted for ties bias-corrected and accelerated (BCa) or normal-based (NB) confidence intervals (CI) to reduce sampling bias, overfitting, and prediction errors.

Results {#Sec7}
=======

Overall, HT occurred in 186 (23.8%) out of 783 cases, whereas SHT was determined in 98 (12.5%). HI-1 was established in 26 (3.3%); HI-2, 120 (15.3%); PH-1, 13 (1.7%); and PH-2, 27 (3.4%) observations. Patients with any HT were more likely to have a poor outcome: death (AHT: RRR, 4.8; 95% CI, 2.2--10.6; *p* \< 0.001; SHT: RRR, 11.7; 95% CI, 6--22.6; *p* \< 0.001), malignant edema (AHT: RRR, 16.7; 95% CI, 5.6--49.2; *p* \< 0.001; SHT: RRR, 52.1; 95% CI, 19.6--138.9; *p* \< 0.001), and dependency (AHT: RRR, 4.4; 95% CI, 2.5--7.7; *p* \< 0.001; SHT: RRR, 30.4; 95% CI, 9.5--97.1; *p* \< 0.001).

There was no difference between AHT and SHT groups with regard to timing (*p* = 0.08): the former, median day 2 (IQR, 1--4); the latter, median day 2 (IQR, 1--3). The median AIS onset time was 6 h (IQR, 2--11). Just under half of all cases (346; 44.2%) were admitted within the 4.5-h therapeutic window; in total, 67 (8.6%) patients were treated with IV rtPA.

The ICC was 0.95 (95% CI, 0.85--0.99; *p* \< 0.001) and 0.78 (95% CI, 0.59--0.88; *p* \< 0.001) for the NIHSS and ASPECTS respectively, which indicated excellent inter-rater agreement. There was no difference between the DC and VC (Table [3](#Tab3){ref-type="table"}).Table 3Baseline Characteristics in the DC and VCDC (*n* = 535)VC (*n* = 248)*p*-ValueClinical data, median (IQR) Age (y)71 (60--78)69 (61--77)0.924 DBP (mm Hg)90 (80--100)100 (80--100)0.025 Height (m)1.65 (1.6--1.72)1.65 (1.58--1.71)0.063 Male sex, *n* (%)289 (54)125 (50.4)0.346 NIHSS8 (4--16)8 (4--16)0.574 Pulse rate (bpm)78 (74--83)78 (74--85)0.155 SBP (mm Hg)160 (140--180)160 (140--180)0.19 Time from onset (h)5.5 (2--11)6 (2.5--11)0.265 Temperature (°C)36.6 (36.4--36.6)36.6 (36.5--36.6)0.194 Weight (kg)78 (68--88)76.7 (68--85)0.476Stroke cause, *n* (%) Large-artery atherosclerosis212 (39.6)109 (44)0.252 Cardioembolism225 (42.1)101 (40.7)0.725 Small-vessel occlusion79 (14.8)33 (13.3)0.587 Other determined etiology7 (1.3)1 (0.4)0.241 Undetermined etiology12 (2.2)4 (1.6)0.562Risk factors, *n* (%) Acute myocardial infarction25 (4.7)8 (3.2)0.348 AF history210 (39.3)94 (37.9)0.719 Alcohol abuse62 (11.6)29 (11.7)0.966 Atherosclerosis528 (98.7)248 (100)0.07 Bleeding history41 (7.7)27 (10.9)0.136 Chronic heart failure62 (11.6)28 (11.3)0.903 Chronic liver failure5 (0.9)7 (2.8)0.045 Chronic renal failure20 (3.7)11 (4.4)0.642 Coronary artery disease191 (35.7)89 (35.9)0.96 Diabetes mellitus142 (26.5)69 (27.8)0.707 Dyslipidemia216 (40.4)103 (41.5)0.759 Hypertension497 (92.9)230 (92.7)0.937 Malignancy10 (1.9)4 (1.6)0.801 Seizures at onset10 (1.9)3 (1.2)0.502 Previous TIA/stroke221 (41.3)116 (46.8)0.151Brain CT, *n* (%) ASPECTS, median (IQR)8 (6--9)8 (6--9)0.708 HMCA sign141 (26.4)66 (26.6)0.939 Leukoaraiosis347 (64.9)168 (67.7)0.429 Left hemispheric stroke286 (53.5)122 (49.2)0.266 Right hemispheric stroke234 (43.7)122 (49.2)0.154 Bihemispheric stroke15 (2.8)4 (1.6)0.314Blood tests, median (IQR) Albumin (g/L), *n* = 513/23341.1 (38.6--43.1)40.7 (38.8--42.9)0.612 ALT (IU/L), *n* = 531/24820 (14--28)19 (13.2--29.8)0.48 AST (IU/L), *n* = 495/22724 (19--31)23 (19--32)0.939 APTT (s)32 (28.8--35.3)31.9 (28.7--34.5)0.299 Bilirubin, total (μmol/L), *n* = 497/23111.5 (8.3--17)11.5 (8--16.1)0.699 Cholesterol, total (mmol/L), *n* = 467/2095.1 (4.3--5.9)5.2 (4.3--6.1)0.286 Creatinine (μmol/L)90.6 (79.3--106)90 (77.4--108)0.851 Fibrinogen (g/L), *n* = 502/2403.2 (2.6--4)3.2 (2.6--4.2)0.985 Glucose (mmol/L)6.8 (5.9--8.3)6.8 (5.9--8.1)0.998 Hematocrit, *n* = 534/2470.43 (0.38--0.46)0.42 (0.37--0.45)0.08 Hemoglobin (g/L), *n* = 535/247141 (128--153)139 (124--150)0.12 INR1.04 (0.96--1.15)1.05 (0.98--1.15)0.361 Platelet count (×10^9^ cells/L)245 (199--306)249.5 (201--301)0.865 Protein, total (g/L), *n* = 523/24267.9 (64.4--71.7)68.4 (64.7--72.7)0.159 Potassium (mmol/L), *n* = 530/2434 (3.7--4.3)4 (3.7--4.3)0.223 PT (s), *n* = 531/24712 (10.9--14.8)12 (11.2--15.3)0.408 RBC (×10^12^ cells/L)4.63 (4.28--4.97)4.55 (4.14--4.93)0.032 Sodium (mmol/L), *n* = 530/242139.5 (138--141.3)139.1 (137--141)0.164 Urea (mmol/L), *n* = 533/2486 (4.7--7.7)5.7 (4.6--7.6)0.403 WBC (×10^9^ cells/L)7.9 (6.5--9.7)7.6 (6.3--9.5)0.285ECG, *n* (%) AF rhythm164 (30.7)77 (31)0.911 HR (bpm), median (IQR)79 (67--91)80 (68--96)0.157 Normal ECG26 (4.9)10 (4)0.607 Other ECG changes259 (48.4)121 (48.8)0.921LVEF (%), *n* = 486/217, median (IQR)57 (50--60)57 (50--61)0.993Chest X-ray, *n* (%) Aortic atherosclerosis462 (86.4)217 (87.5)0.661 Cardiomegaly401 (75)207 (83.5)0.008 Normal chest X-ray28 (5.2)13 (5.2)0.996 Pleural effusion62 (11.6)20 (8.1)0.134 Pneumonia48 (9)23 (9.3)0.891 Pulmonary congestion215 (40.2)109 (44)0.32Antithrombotic medication, *n* (%) Anticoagulant28 (5.2)14 (5.6)0.812 Antiplatelet390 (73)201 (81)0.014 Anticoagulant + antiplatelet66 (12.3)17 (6.9)0.02 IV rtPA51 (9.5)16 (6.5)0.152Outcome, *n* (%) Any HT126 (23.6)60 (24.2)0.844 SHT69 (12.9)29 (11.7)0.636 HI-122 (4.1)4 (1.6)0.069 HI-282 (15.3)38 (15.3)0.999 PH-19 (1.7)4 (1.6)0.944 PH-213 (2.4)14 (5.6)0.022 Death34 (6.4)19 (7.7)0.499 Malignant cerebral edema32 (6)14 (5.6)0.852 Dependency325 (60.7)147 (59.3)0.695*Note*: *APTT* stands for Activated partial thromboplastin time, *DBP* Diastolic blood pressure, *INR* International normalized ratio, *PT* Prothrombin time, *RBC* Red blood cells, *SBP* Systolic blood pressure, and *WBC* White blood cells

Univariate analysis was summarized in Table [4](#Tab4){ref-type="table"}.Table 4Univariate Analysis in the DC Using the MI DatasetAny HT (*n* = 126)No HT (*n* = 409)OR (95% CI)*p*-ValueFMIRIVREClinical data, median (IQR) Age (y)74 (62--79)70 (60--77)1.016 (0.998--1.034)0.077001 DBP (mm Hg)90 (80--100)90 (80--100)0.992 (0.979--1.005)0.217001 Height (m)1.65 (1.6--1.7)1.66 (1.6--1.73)0.983 (0.961--1.006)0.138001 Male sex, *n* (%)60 (47.6)229 (56)0.715 (0.479--1.066)0.1001 NIHSS20 (14--23)6 (3--10)1.253 (1.206--1.302)\<0.001001 Pulse rate (bpm)80 (74--88)78 (72--80)1.037 (1.021--1.053)\<0.001001 SBP (mm Hg)155 (140--180)160 (140--179)0.999 (0.992--1.006)0.683001 Temperature (°C)36.6 (36.4--36.7)36.6 (36.4--36.6)1.658 (0.904--3.041)0.102001 Weight (kg)76 (65--90)79.5 (70--87)0.998 (0.986--1.01)0.759001Risk factors, *n* (%) Acute myocardial infarction16 (12.6)9 (2.2)6.39 (2.75--14.851)\<0.001001 AF history81 (63.8)129 (31.6)3.808 (2.508--5.783)\<0.001001 Alcohol abuse11 (8.7)51 (12.5)0.664 (0.335--1.316)0.241001 Atherosclerosis124 (97.6)404 (99)0.409 (0.09--1.853)0.246001 Bleeding history9 (7.1)32 (7.8)1.116 (0.518--2.405)0.78001 Chronic heart failure24 (18.4)38 (9.3)0.441 (0.253--0.768)0.004001 Chronic liver failure1 (0.8)4 (1)0.802 (0.89--7.237)0.844001 Chronic renal failure7 (5.5)13 (3.2)1.772 (0.691--4.543)0.233001 Coronary artery disease56 (44.1)135 (33.1)1.595 (1.062--2.395)0.024001 Diabetes mellitus39 (30.7)103 (25.2)1.312 (0.847--2.034)0.224001 Dyslipidemia41 (32.3)175 (42.9)0.635 (0.417--0.967)0.034001 Hypertension118 (92.9)379 (92.9)0.997 (0.459--2.166)0.994001 Malignancy4 (3.1)6 (1.5)2.179 (0.605--7.846)0.233001 Previous TIA/stroke51 (40.2)170 (41.7)0.939 (0.626--1.41)0.763001 Seizures at onset0 (0)10 (2.5)--0.075^a^001Brain CT, *n* (%) ASPECTS, median (IQR)4 (1--6)8 (7--9)0.499 (0.44--0.567)\<0.001001 HMCA sign88 (69.3)54 (13.2)14.792 (9.213--23.749)\<0.001001 Leukoaraiosis87 (68.5)260 (63.7)1.238 (0.809--1.894)0.325001 Left hemispheric stroke73 (58)213 (52)1.291 (0.863--1.931)0.214001 Right hemispheric stroke53 (42)181 (44.3)0.898 (0.6--1.344)0.602001 Bihemispheric stroke0 (0)15 (3.7)--0.028^a^001Stroke cause, *n* (%) Large-artery atherosclerosis41 (32.5)171 (41.8)0.671 (0.441--1.023)0.064001 Cardioembolism79 (62.7)146 (35.7)3.028 (2.002--4.58)\<0.001001 Small-vessel occlusion0 (0)79 (19.3)--\<0.001^a^001 Other determined etiology1 (0.8)6 (1.5)0.537 (0.064--4.506)0.567001 Undetermined etiology5 (4)7 (1.7)2.373 (0.74--7.612)0.146001LVEF (%), *n* = 120/366, median (IQR)55 (46.25--59)58 (53--61.25)0.957 (0.938--0.975)\<0.0010.0260.0270.998Chest X-ray, *n* (%) Aortic atherosclerosis114 (89.8)348 (85.3)1.512 (0.801--2.85)0.203001 Cardiomegaly109 (85.8)292 (71.6)2.406 (1.398--4.141)0.002001 Normal chest X-ray3 (2.4)25 (6.1)0.371 (0.11--1.249)0.109001 Pleural effusion25 (19.7)37 (9.1)2.458 (1.414--4.271)0.001001 Pneumonia21 (16.5)27 (6.6)2.796 (1.52--5.143)0.001001 Pulmonary congestion78 (61.4)137 (33.6)3.149 (2.085--4.755)\<0.001001ECG, *n* (%) AF rhythm70 (55.1)94 (23)4.102 (2.699--6.236)\<0.001001 HR (bpm), median (IQR)90 (73--107)75 (65.25--88)1.034 (1.023--1.045)\<0.001001 Normal ECG3 (2.4)23 (5.6)0.405 (0.12--1.372)0.146001 Other changes68 (53.5)191 (46.8)1.309 (0.878--1.952)0.186001Blood tests, median (IQR) Albumin (g/L), *n* = 122/39140.4 (38.4--42.8)41.2 (38.7--43.2)0.957 (0.905--1.012)0.1240.0260.0260.998 ALT (IU/L), *n* = 126/40419 (15--29)20 (14--27.5)1.001 (0.992--1.01)0.8490.0010.0011 APPT (s)31.7 (28.1--35.1)32.2 (29--35.4)0.993 (0.97--1.015)0.52001 AST (IU/L), *n* = 120/37527 (20.4--32)23 (18--30.3)1.001 (0.995--1.008)0.6970.0310.0320.998 Bilirubin, total (μmol/L), *n* = 117/38014.04 (9.3--19.6)10.9 (8.1--15.4)1.043 (1.018--1.068)0.0010.0670.0710.996 Creatinine (μmol/L)89 (77.7--104.9)91 (79.9--106.7)0.998 (0.991--1.006)0.638001 Cholesterol, total (mmol/L), *n* = 113/3544.8 (4--5.8)5.2 (4.4--5.9)0.805 (0.676--0.96)0.0160.0380.0390.998 Fibrinogen (g/L), *n* = 121/3813.5 (2.7--4.4)3.11 (2.6--3.9)1.266 (1.087--1.475)0.0020.040.0410.997 Glucose (mmol/L)7.5 (6.4--9.7)6.6 (5.8--7.9)1.061 (1.009--1.117)0.021001 Hematocrit, *n* = 126/4070.43 (0.38--0.46)0.42 (0.38--0.46)0.993 (0.958--1.029)0.679001 Hemoglobin (g/L)141 (127--152)141 (128.625--153)0.997 (0.987--1.006)0.515001 INR1.06 (0.98--1.15)1.04 (0.95--1.12)0.919 (0.467--1.808)0.808001 Platelet count (×10^9^ cells/L)236 (186--286)248 (206--309)0.998 (0.995--1)0.048001 Potassium (mmol/L), *n* = 126/4044 (3.7--4.3)4 (3.6--4.2)1.247 (0.862--1.802)0.2410.0090.0090.999 Protein, total (g/L), *n* = 126/39767.6 (64--71.2)68 (64.8--71.7)0.987 (0.953--1.021)0.4440.0060.0061 PT (s), *n* = 126/40512.2 (11.3--13.8)11.8 (10.8--16.1)0.976 (0.932--1.022)0.3050.0020.0021 RBC (×10^12^ cells/L)4.64 (4.23--5.01)4.63 (4.3--4.97)0.941 (0.664--1.332)0.73001 Sodium (mmol/L), *n* = 126/404139.3 (138--141.9)139.5 (138--141.3)1.015 (0.957--1.077)0.6240.0110.0110.999 Urea (mmol/L), *n* = 126/4066.36 (5.2--8.5)5.81 (4.5--7.3)1.089 (1.02--1.161)0.01001 WBC (×10^9^ cells/L)8.8 (6.6--11.4)7.8 (6.5--9.3)1.145 (1.071--1.225)\<0.001001Antithrombotic medication, *n* (%) Anticoagulant5 (4)23 (5.6)0.693 (0.258--1.863)0.468001 Antiplatelet68 (54)322 (78.7)0.317 (0.208--0.483)\<0.001001 Anticoagulant + antiplatelet29 (23)37 (9.1)3.006 (1.76--5.132)\<0.001001 IV rtPA24 (19)27 (6.6)3.329 (1.842--6.015)\<0.001001*Note*: ^a^Perfect predictor. Instead of BLR, Pearson χ^2^ test was used

Multivariate analysis {#Sec8}
---------------------

Although univariate *p*-values for leukoaraiosis and international normalized ratio (INR) were above our acceptable threshold, we included them in the multivariate analysis because some authors had proposed them as risk factors \[[@CR18], [@CR19]\]. As a result of fitting a multivariate BLR model, seven variables were kept in the final equation (Table [5](#Tab5){ref-type="table"}).Table 5Multivariate Analysis (DC, *n* = 535)CoefficientBiasBootstrap SEOR (95% BCa CI)*p*-ValueASPECTS−0.472−0.0260.0920.62 (0.52--0.75)\<0.001AF on ECG1.1570.0290.4053.18 (1.47--6.66)0.002Male sex0.880.0550.3812.41 (1.12--5.15)0.027NIHSS0.1350.0040.0291.15 (1.08--1.21)\<0.001HR on ECG (bpm)0.0270.0010.0081.03 (1.01--1.04)0.001HMCA sign1.0410.0010.3462.83 (1.44--5.45)0.002INR−3.304−0.1790.920.04 (0.01--0.22)\<0.001*Note*: *SE* stands for Standard error

Swapping AF on ECG for the AF history variable increased the Bayesian and Akaike information criteria by 1.18, which slightly favored the initial model. Overall, the multivariate BLR model was statistically significant (Wald test: χ^2^(7), 87.76; *p* \< 0.001; −2log-likelihood, 271.93; Cox-Snell pseudo-R^2^, 0.44; Nagelkerke pseudo-R^2^, 0.67). It explained variance of 78.4% (variance of latent variable, *y*\* = 11.13; error, ε = 3.29) and fitted the data well (Hosmer-Lemeshow goodness of fit test for 10 groups: χ^2^(8), 6.87; *p* = 0.551). Neither significant interactions nor polynomial terms were found.

There was no specification error (Pregibon's link test: linear predicted value, *p* \< 0.001; linear predicted value squared, *p* = 0.54). Assumption of linearity between independent variables and log odds was confirmed by the LOWESS graph. Multicollinearity was not an issue: the extrema of the variance inflation factor were 1.01 and 2.29.

Although standardized Pearson and deviance residuals exceeded 2 in a few observations, their leverage and Pregibon's influential statistics (dbeta) turned out to be very small. Moreover, removing those observations did not significantly change the equation coefficients. Influence of each individual observation on the coefficient estimate (not adjusted for the covariate pattern), dfbeta, was not strong. However, the most sensitive was the INR variable (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Multivariate BLR Model Diagnostics. **a** LOWESS graph, bandwidth = 0.8. Each hollow circle is an individual observation. **b** Influence of each individual observation on the coefficient estimate (dfbeta). **c** Standardized Pearson residuals. **d** Deviance residuals. **e** Leverage. The dashed line corresponds to the 3-fold leverage mean. **f** Pregibon's influential statistics (dbeta)

Model sensitivity, specificity, positive and negative predictive values were 76.2%, 95.6%, 84.2%, and 92.9% respectively. The model accurately classified 91% of the observations, whereas the equation without any independent variables classified correctly only 76.5% of the cases.

Based on PP tables and plots, we divided each predictor into categories and allocated them points according to the PP range in order to draw the HTI score. Given the Doornik-Hansen test (χ^2^(14), 3665.64; *p* \< 0.001), the distribution of the newly derived HTI items was not multivariate normal (Table [6](#Tab6){ref-type="table"}; Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Table 6Derivation of the HTI ScorePP Range^a^Allocated PointsASPECTS 10--70.1--0.20 6--50.2--0.31 4--30.3--0.42 2--0\>0.43NIHSS 0--110.1--0.20 12--170.2--0.31 18--230.3--0.42  \>23\>0.43INR  \>1.82\<0.10 1.26--1.820.1--0.21  ≤1.25\>0.22HR on ECG (bpm) 40--680.1--0.20 69--1120.2--0.31 113--1470.3--0.42  \>147\>0.43AF on ECG0.2--0.31HMCA sign0.2--0.31Male sex0.2--0.31*Note*: ^a^Holding all other variables constant at their observed values Fig. 2Derivation of HTI Score. **a** ASPECTS. **b** NIHSS. **c** INR. **d** HR on ECG. **e** HMCA sign. **f** AF on ECG. **g** Sex. Grey areas and capped lines represent 95% CI. Numbers at the top indicate HTI scores; at the bottom, units of variables. The confounders are held constant at their observed values Fig. 3KDE for HTI Items. Kernel = Epanechnikov for all items. **a** ASPECTS; bandwidth = 0.1899. **b** NIHSS; bandwidth = 0.1899. **c** INR; bandwidth = 0.116. **d** HR on ECG; bandwidth = 0.1528. **e** Sex; bandwidth = 0.1278. **f** HMCA sign; bandwidth = 0.113. **g** AF on ECG; bandwidth = 0.1182

Factor analysis {#Sec9}
---------------

The Bartlett's test of sphericity (χ^2^(21), 721.74; *p* \< 0.001) and the Kaiser-Meyer-Olkin measure of 0.71 demonstrated that the HTI items did have patterned relationships and were sufficient for EFA. PF EFA established a unidimensional scale, i.e. there was only one factor that explained a cumulative variance of 82.8%. By means of PCF EFA, the factor was discovered to consist of cerebral (ASPECTS, NIHSS, and HMCA sign) and extracerebral (resting heart rate (HR) on ECG, AF on ECG, sex, and INR) components as we called them. However, the resting HR on ECG, INR, and sex variables showed high uniqueness values and low factor loadings; therefore, we had to drop them. The final 4-item HTI was strongly supported by subsequent CFA (Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}; Fig. [4](#Fig4){ref-type="fig"}).Table 7Factor/Component Loadings and Uniqueness in EFA of the HTI ItemsNo RotationVarimax RotationPromax RotationUniquenessF1C1C2C1C2C1C2PFPCFASPECTS0.840.860.90.90.290.17HR on ECG0.340.43−0.60.730.750.890.45INR0.56−0.54−0.580.990.68NIHSS0.830.860.890.890.320.18Male sex−0.33−0.43−0.4−0.390.890.76HMCA sign0.810.840.360.910.910.350.18AF on ECG0.560.65−0.590.830.820.690.23Eigenvalue2.582.981.38NANANANANANAVariance, %82.842.519.7637.5624.739.3328.1NANA*Note*: Empty cells indicate that absolute factor or component loading value is \<0.3. *C1* stands for Component 1, *C2* Component 2, *F1* Factor 1, and *NA* Not applicable Table 8CFA. Goodness of Fit StatisticsF1-V4F1-V5F1-V6F1-V7F2DescriptionLikelihood ratio χ^2^(2/5/9/14/13)0.556.1787.26103.6618.19Model vs. saturated  *p*-value0.78\<0.001\<0.001\<0.0010.15 χ^2^(6/10/15/21/21)594.14664.18711.01727.4727.4Baseline vs. saturated  *p*-value\<0.001\<0.001\<0.001\<0.001\<0.001Satorra-Bentler test χ^2^(2/5/9/14/13)0.450.9682.63100.3118.08Model vs. saturated  *p*-value0.82\<0.001\<0.001\<0.0010.16 χ^2^(6/10/15/21/21)475.75574.14649.06684.79684.79Baseline vs. saturated  *p*-value\<0.001\<0.001\<0.001\<0.001\<0.001Population error RMSEA\<0.0010.1380.1270.1090.027Root mean squared error of approximation 90% CI0--0.0560.107--0.1720.104--0.1530.09--0.130--0.054  *p*-close0.932\<0.001\<0.001\<0.0010.909Probability RMSEA ≤0.05 RMSEA-SB\<0.0010.1310.1240.1070.027Satorra-Bentler RMSEAInformation criteria AIC3726.824682.795446.186121.686038.21Akaike information criterion BIC3778.214747.025523.266211.66132.42Bayesian information criterionBaseline comparison CFI10.920.890.870.99Comparative fit index TLI10.840.810.810.99Tucker-Lewis index CFI-SB10.920.880.870.99Satorra-Bentler CFI TLI-SB10.840.810.810.99Satorra-Bentler TLISize of residuals SRMR0.010.080.080.080.03Standardized root mean squared residual CD0.830.830.830.830.96Coefficient of determination*Note*: *F1-V4* indicates one-factor model with 4 variables (ASPECTS, NIHSS, HMCA sign, and AF on ECG), *F1-V5* one-factor model with 5 variables (4 previous variables + HR on ECG), *F1-V6* one-factor model with 6 variables (5 previous variables + sex), *F1-V7* one-factor model with 7 variables (6 previous variables + INR), and *F2* two-factor model with factor 1 (ASPECTS, NIHSS, and HMCA sign) and factor 2 (AF on ECG, INR, sex, and HR on ECG) Fig. 4Scree Plot. EFA by using (**a**) PF and (**b**) PCF methods

Once the HTI was definitively established, crude PP of any HT was computed for each score by using BLR. Although the dropped items were no longer a part of the HTI, we put them into the BLR equation for confounding adjustment. Unsurprisingly, the confounders exerted only a minor influence on the overall HTI OR by increasing it up to 12% and had no significant effect on the OR of the separate HTI items (Tables [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"} and [11](#Tab11){ref-type="table"}; Fig. [5](#Fig5){ref-type="fig"}).Table 9BLR Coefficients, Bias, and Bootstrap SE for the HTI (DC, *n* = 535)CrudeAdjusted^a^CoefficientBiasBootstrap SECoefficientBiasBootstrap SEHTI, overall0.9410.0120.0851.030.0270.109HTI items ASPECTS0.8150.0310.1650.9140.0470.188 NIHSS0.9580.020.1751.0530.0380.201 HMCA sign1.157−0.0050.3361.2140.0080.347 AF on ECG1.1150.0020.3171.2140.0310.403*Note*: ^a^Confounders (sex, INR, and HR on ECG) were measured in allocated points (Table [6](#Tab6){ref-type="table"}) Table 10OR for the HTI (DC, *n* = 535)CrudeAdjusted^a^Crude vs. Adjusted^b^OR (95% BCa CI)*p*-ValueOR (95% BCa CI)*p*-Valueχ^2^(1)*p*-ValueHTI, overall2.56 (2.19--3.02)\<0.0012.80 (2.32--3.39)\<0.0014.030.045HTI items ASPECTS2.26 (1.64--3.07)\<0.0012.49 (1.75--3.54)\<0.0012.40.121 NIHSS2.61 (1.88--3.7)\<0.0012.87 (1.91--4.15)\<0.0011.910.167 HMCA sign3.18 (1.71--6.24)0.0013.37 (1.73--6.89)\<0.0010.330.565 AF on ECG3.05 (1.71--5.88)\<0.0013.37 (1.55--7.4)0.0030.270.605*Note*: ^a^Confounders (sex, INR, and HR on ECG) were measured in allocated points (Table [6](#Tab6){ref-type="table"}). ^b^Wald test was performed Table 11PP of Any HT for Each HTI ScoreHTI ScoreCrudeAdjusted^a^PP (95% CI)*p*-ValuePP (95% CI)*p*-Value00.03 (0.015--0.044)\<0.0010.027 (0.011--0.042)0.00110.073 (0.047--0.099)\<0.0010.07 (0.043--0.098)\<0.00120.168 (0.126--0.21)\<0.0010.169 (0.125--0.213)\<0.00130.34 (0.274--0.407)\<0.0010.346 (0.275--0.417)\<0.00140.569 (0.479--0.66)\<0.0010.571 (0.474--0.668)\<0.00150.772 (0.686--0.858)\<0.0010.768 (0.676--0.861)\<0.00160.897 (0.838--0.955)\<0.0010.893 (0.829--0.957)\<0.00170.957 (0.925--0.989)\<0.0010.956 (0.92--0.992)\<0.00180.983 (0.967--0.998)\<0.0010.983 (0.965--1.0)\<0.001*Note*: ^a^Confounders (sex, INR, and HR on ECG) were held constant at their observed values Fig. 5Calibration Plot. The scatterplots display PP of any HT for individual observations obtained from multivariate analysis (Table [5](#Tab5){ref-type="table"}) and arranged by the HTI score: (**a**) The DC, (**b**) The VC. The superimposed connected line graph drawn from the DC demonstrates PP of any HT for each HTI score with 95% CI adjusted for sex, INR, and HR on ECG (Table [11](#Tab11){ref-type="table"}). The confounders are held constant at their observed values

KDE for PP of any HT was equal between the multivariate BLR model and HTI score (D = 0.184; *p* = 0.371). Thus, the HTI score was considered as a surrogate for the multivariate BLR model (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6KDE for PP of Any HT. Kernel = Epanechnikov, bandwidth = 0.0623. The solid line represents the multivariate BLR model (Table [5](#Tab5){ref-type="table"}); the dashed line, the HTI score (Table [11](#Tab11){ref-type="table"})

ICR and ROC analysis {#Sec10}
--------------------

Given multiple reliability tests, HTI ICR was considered to be fair enough for the DC and VC alike. There was also no difference in the AUC (χ^2^(1), 0.01; *p* = 0.93) and KDE for the HTI scores (D = 0.02; *p* = 1.0) between both cohorts (Table [12](#Tab12){ref-type="table"}; Fig. [7](#Fig7){ref-type="fig"}).Table 12HTI ICR and ROC AnalysisDC, *n* = 535VC, *n* = 248Ordinal α0.820.83Guttman bounds λ~2~0.830.85 λ~4~0.840.88Raykov's ρ0.810.81McDonald's ω Categorical (95% BCa CI)0.81 (0.77--0.84)0.82 (0.76--0.86) Hierarchical0.830.87 Total0.890.91Greatest lower bound0.840.89ROC analysis (95% NB CI) AUC0.85 (0.82--0.89)0.83 (0.78--0.88) Youden index0.7 (0.63--0.78)0.67 (0.57--0.77) Cutpoint2 (1--3)2 (1--3) Sensitivity0.82 (0.73--0.9)0.8 (0.66--0.94) Specificity0.89 (0.8--0.97)0.87 (0.73--1.0) Fig. 7KDE for HTI Scores. Kernel = Epanechnikov, bandwidth = 0.5697. The solid line represents the DC; the dashed line, the VC

Taking into account that alternative scores had been developed in AIS patients with slightly different clinical settings, the HTI prognostic performance was considered to be at least non-inferior to the competitors (Tables [13](#Tab13){ref-type="table"} and [14](#Tab14){ref-type="table"}).Table 13Comparison of Different Composite Scores for Predicting HT in AIS PatientsScorePredictorsSample SizeCerebral Vascular TerritoryPredicted OutcomeIV rtPA SettingsCucchiara \[[@CR6]\]ClinicalAge, NIHSS1205AnyAny HTYesLaboratoryGlucose, platelet countGRASPS \[[@CR9]\]ClinicalAge, ethnicity, NIHSS, sex, SBP10,242AnySHTYesLaboratoryGlucoseHAS-BLED \[[@CR46]\]ClinicalAge, alcohol abuse, bleeding history, drugs, SBP, stroke/TIA3978AnyMajor Bleeding^a^NoLaboratoryLiver and renal function tests, INRHAT \[[@CR5]\]ClinicalDiabetes mellitus, NIHSS400AnySHTYesImagingASPECTSLaboratoryGlucoseHeRS \[[@CR31]\]ClinicalAge345AnyAny HTRegardlessImagingInfarct volumeLaboratoryEstimated glomerular filtration rateHTIClinicalNIHSS783MCAAny HTRegardlessImagingASPECTS, HMCA signLaboratoryAF on ECGiScore \[[@CR32]\]ClinicalAF, age, cancer, chronic heart failure, NIHSS, preadmission disability, renal dialysis, sex, stroke subtype1696AnyAny HTYesLaboratoryGlucoseSEDAN \[[@CR8]\]ClinicalAge, NIHSS1802AnySHTYesImagingASPECTS, HMCA signLaboratoryGlucoseSITS-SICH \[[@CR7]\]ClinicalAge, antiplatelet medication, hypertension, NIHSS, stroke onset to treatment time, SBP, weight31,627AnySHTYesLaboratoryGlucoseSPAN-100 \[[@CR33]\]ClinicalAge, NIHSS624AnyAny HTRegardless*Note*: ^a^1-year risk for major bleeding (intracranial, hospitalization, hemoglobin decrease \> 2 g/L, and/or transfusion) in a cohort of real-world patients with AF Table 14AUC Comparison Between the HTI and Alternative Scores (VC, *n* = 248)ScoreAUC (95% NB CI)χ^2^(1)*p*-ValueHTI0.83 (0.78--0.88)----Cucchiara0.72 (0.67--0.77)31.6\<0.001GRASPS0.80 (0.75--0.84)10.98\<0.001HAS-BLED0.53 (0.47--0.59)86.47\<0.001HAT0.82 (0.77--0.88)4.340.037HeRS^a^0.81 (0.75--0.86)4.110.043iScore0.83 (0.79--0.87)2.930.087SEDAN0.82 (0.76--0.87)11.59\<0.001SITS-SICH^b^0.72 (0.66--0.78)25.06\<0.001SPAN-1000.59 (0.53--0.65)111.26\<0.001*Note*: ^a^Infarct volume was calculated on follow-up CT scans (≥12 h after the initial imaging) by using the ABC/2 formula. ^b^For patients, who were not eligible for IV rtPA, stroke onset to treatment time was considered as stroke onset to admission time

Discussion {#Sec11}
==========

The incidence of HT showed in our study echoes the rate reported in literature. We have also reaffirmed the concept that AHT is not clinically innocuous. The study unequivocally reiterates infarct size, stroke severity, large-artery occlusion, and cardioembolism defined by ASPECTS, NIHSS, HMCA sign, and AF respectively are well-established independent HT predictors \[[@CR20], [@CR21]\]. In our HTI score, we use the presence of AF on ECG at admission rather than AF history for the reason discussed in the Results. However, other known predictors -- platelet count, cholesterol level, age, hypertension, renal failure, hyperglycemia, and leukoaraiosis -- have shown no independent association with any HT in our cohort; similar results were obtained by other authors \[[@CR22]--[@CR26]\]. The mechanism of this association needs to be explored.

Although women tend to be more likely HT-positive in our univariate BLR model, multivariate analysis reveals the opposite. It seems there is still controversy about the sex propensity for developing HT \[[@CR27]\].

Accelerated HR at rest is known to be associated with an increased risk of stroke especially recurrent \[[@CR28]\]. Since AIS commonly induces change in cardiovascular responses, post-stroke HR at admission could be a potential marker to identify patients at risk for short-term deterioration and long-term poor outcomes \[[@CR29]\]. To the best of our knowledge, we have not found any literature, concerning HR correlations with HT. Here, we report that the more the HR is accelerated on ECG (but not the pulse rate), the more likely HT can occur.

Hypercoagulability at AIS onset measured by INR and other tests is known to be associated with an increased thrombotic tendency. As long as the hypercoagulable state persists, both arterial and venous thromboembolic recurrences can be expected. The association of these coagulation abnormalities with HT is not always clear \[[@CR30]\]. As we have shown here, the less the INR, the higher the risk of HT.

Having identified seven independent variables in our multivariate analysis, we applied the PP range followed by factor analysis to assigned HTI scores and to regroup HTI variables into a limited set of clusters based on shared variance. We assume probability is more intuitive for interpreting than OR. In contrast, authors of other predictive tools allocated scores based on OR changes only \[[@CR5]--[@CR9], [@CR31]--[@CR33]\]. While BLR analyzes effects of each individual predictor on the dependent variable, factor analysis isolating constructs and concepts treats the model as a whole \[[@CR34]\]. Thus, it helped us to avoid overfitting.

Among the compared predictive tools, the SPAN-100 and HeRS were derived from the cohorts, which were very similar in clinical settings to ours (Table [13](#Tab13){ref-type="table"}). As to the former, we have reaffirmed that it is far inferior in prognostic performance to other scores \[[@CR35], [@CR36]\]. Regarding the latter, the infarct size was measured in different ways: we chose the ASPECTS estimation on non-contrast CT, whereas the HeRS scored it in milliliters on magnetic resonance diffusion-weighted imaging (DWI MRI). Although both approaches are widely acceptable in hyperacute stroke settings, the ASPECTS is more suitable for non-contrast CT assessment, while the lesion volume can easily be quantified on DWI \[[@CR37]--[@CR39]\]. Furthermore, the ASPECTS, as well as the NIHSS, correlates strongly with the infarct volume (ASPECTS: Spearman ρ, −0.88; *p* \< 0.001; NIHSS: Spearman ρ, 0.71; *p* \< 0.001; VC, *n* = 248), but moderately with each other (Spearman ρ, −0.66; *p* \< 0.001; VC, *n* = 248). If the stroke volume variable had been added to our multivariate BLR equation, a multicollinearity issue would have occurred. We also suppose that a combination of clinical and imaging features is more reliable than the imaging data alone. To make our HTI score as much easy-to-use as possible, we have purposely refrained from MRI since CT is readily available in the most hospitals. Moreover, the HeRS score is computationally complicated; therefore, it seems less attractive from the practical point of view.

There are some important peculiarities between posterior and anterior circulation stroke. The differences include the value of screening instruments, optimum diagnostic modalities, clinical features, and outcomes \[[@CR40], [@CR41]\]. For instance, patients with vertebrobasilar infarction have lower NIHSS score and HT rates, less often AF, higher blood glucose level and rates of false-negative DWI findings, more WBC counts, and a better long-term outcome than those with carotid stroke \[[@CR42]--[@CR44]\]. However, all aforementioned tools predict HT regardless of the vascular basin (Table [13](#Tab13){ref-type="table"}). Moreover, scores with imaging modalities, like the HAT and SEDAN, include CT signs of MCA stroke only. Meanwhile, a scoring system, the pc-ASPECTS, has been developed and validated for posterior circulation stroke \[[@CR45]\]. Thus, the accuracy of predictive tools could be further improved by distinguishing the infarcted vascular basins; therefore, we have decided to restrict our study to the MCA territory.

There are a few limitations in our study. A relatively small, but sufficient for statistical inferences, sample size and lack of ethnic and racial diversity could be a source of potential bias. Almost all patients came from our local community, which was populated with Russian, Tatar, and Jewish ethnic groups; there were no patients of African, Asian or Hispanic origin. Furthermore, AIS patients following endovascular interventions were excluded from the analysis due to a small number of observations. Although some clinical and imaging data were collected prospectively, the research was retrospective in nature. As a result, we were not blinded to the outcome. The study was also confined to a single clinical center; to cope with that bias, we used bootstrapping. Finally, prospective multicenter external validation would be desirable.

Conclusions {#Sec12}
===========

The HTI is a four-item tool composed of ASPECTS, NIHSS, HMCA sign, and presence of AF on ECG at admission. The total score ranges from zero to eight. The higher the score, the more likely HT can occur. Knowing probability of any HT in advance could exert a significant influence on decision making to reinstitute anticoagulation in AIS patients with AF. It is a simple yet reliable instrument to predict any HT within 2 weeks after onset of AIS in the MCA territory regardless of the use of IV rtPA.
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:   Alanine transaminase
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:   Area under the ROC curve
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:   Binary logistic regression
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:   Confirmatory factor analysis
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:   Hemorrhagic infarction type 2
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:   Hemorrhagic transformation index
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:   Internal consistency reliability
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:   International normalized ratio
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:   Intravenous recombinant tissue plasminogen activator
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:   Kernel density estimate
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:   Locally weighted scatterplot smoothing
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:   Middle cerebral artery

MCMC

:   Markov chain Monte Carlo
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:   Multiple imputation
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:   Magnetic resonance imaging
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:   Normal-based

NIHSS

:   National Institutes of Health Stroke Scale
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:   Odds ratio
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:   Principal component factor
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PH-1

:   Parenchymal hematoma type 1

PH-2

:   Parenchymal hematoma type 2

PP

:   Predicted probability

PT

:   Prothrombin time

RBC

:   Red blood cells

RE

:   Relative efficiency

RIV

:   Relative increase in variance

ROC

:   Receiver operating characteristic

RRR

:   Relative risk ratio

SBP

:   Systolic blood pressure

SE

:   Standard error

SHT

:   Symptomatic hemorrhagic transformation

TIA
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